In the final months of the Reich, Nazi leaders pushed Operation Werewolf as a sabotage and assassination program meant to ...

Werewolf Therapeutics, Inc. develops modified cytokines for cancer treatment, including WTX-124, a modified IL-2, and WTX-330, a modified IL-12. Xilio Therapeutics out-licensed their modified IL-12 to ...

Director Luke Evnin reported selling shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) common stock over three days, with the transactions totaling approximately $61,787. The sales occurred between ...

Get the latest news on Werewolf Therapeutics stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Werewolf Therapeutics performance ...

Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Werewolf Therapeutics (HOWL – Research Report) yesterday and set a price target of $9.00. The company’s shares closed ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Director Luke Evnin reported selling shares of Werewolf Therapeutics Inc (NASDAQ:HOWL), a micro-cap biotech company valued at just $31.07 million, in three separate transactions, with the total value ...